Results 91 to 100 of about 7,495,371 (267)

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

open access: yesMolecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li   +10 more
wiley   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

Mapping UK hazards [PDF]

open access: yes, 2010
The BGS has a 175-year history of mapping and recording geology including unstable land. However, public awareness of such potential problems was not awakened until the Aberfan disaster, 44 years ago, when a school was buried by a landslide from a coal
Cooper, Anthony
core  

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

The New Economics Foundation on tackling the housing crisis with Hanna Wheatley

open access: yesUrban Transcripts, 2020
Hanna Wheatley is a Senior Researcher in NEF (New Economics Foundation), mainly working on housing and land, currently leading NEF’s work on the public land sale in the UK.
Yiorgos Papamanousakis
doaj  

UK General Election-2024: Labour’s Untruimpant Triumph [PDF]

open access: yesСовременная Европа
The parliamentary elections in Britain in 2024 brought the expected victory of the Labour Party and a crushing defeat to the Conservatives. However, the success of the Labour party is due to its tactics in the conditions of a majority electoral system ...
Elena V. Ananieva
doaj   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

open access: yesMolecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli   +7 more
wiley   +1 more source

Transformation of Migration Policy of the Republic of Ireland [PDF]

open access: yesСовременная Европа
In 2023, Dublin experienced massive anti-immigrant riots amid a growing number of asylum seekers in the Republic of Ireland. These events clearly demonstrated that government was gradually losing control of the situation and was unable to fully ensure ...
Oleg V. Okhoshin
doaj   +1 more source

UK doctors united [PDF]

open access: yesFamily Practice, 2018
Harm van Marwijk, Wesley Scott-Smith
openaire   +3 more sources

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy